ArticleEuropean journal of dentistry2026
Investigating GSK-3β as a Potential Prognostic Marker for Metastasis in Head and Neck Squamous Cell Carcinoma: A Preliminary Study on the Crossroads of GABAergic and Wnt Signaling.
Article in European journal of dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study was to determine whether glycogen synthase kinase-3β (GSK-3β) mediates the link between γ-aminobutyric-acid (GABA) signaling and Wnt/β-catenin activation in the progression of head and neck squamous cell carcinoma (HNSCC) and to evaluate whether tumor GSK-3β expression can predict cervical nodal metastasis. Materials and Methods: Forty patients diagnosed with primary HNSCC supplied paired specimens of normal, dysplastic, and tumor tissues. Immunohistochemistry was performed for GABA-BR1/2, β-catenin, and GSK-3β. Nonparametric tests, Spearman's correlation, and multivariable logistic regression (adjusted for age, sex, T-stage, and site) were utilized to investigate clinicopathological associations. Receiver operating characteristic analysis was applied to evaluate the predictive performance for metastasis. Results: The expression of GABA-BR1/2 and nuclear β-catenin increased progressively from normal mucosa to dysplasia to carcinoma (all Conclusion: GSK-3β appears to integrate GABAergic and Wnt/β-catenin signaling and may serve as a robust, independent biomarker of metastatic risk in HNSCC. Although preliminary, these findings support the potential clinical value of GSK-3β and warrant validation in larger, multicenter cohorts before considering its incorporation into risk stratification models or targeted therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.